Menu
1 min read · estimated
APPROVED USE
What FDA approved
First generic 15 mg and 45 mg tablets for adults with chronic-phase CML resistant or intolerant to at least two kinase inhibitors, advanced-phase CML or Ph-positive ALL when no other kinase inhibitor is indicated, or T315I-positive CML or Ph-positive ALL.
LAMPGEN ANALYSIS
Why it matters
The decision added a generic BCR::ABL1 inhibitor for labeled leukemia settings.
What research teams should watch
Check the approved strengths, disease phase and prior TKI history, and distinguish final approval from commercial launch.
PRIMARY RECORDS